Nasdaq:APLS

Received U.S. FDA filing acceptance of NDA with Priority Review designation for intravitreal pegcetacoplan for treatment of geographic atrophy; PDUFA target action date of November 26, 2022Achieved $15.7 million in Q2 2022 EMPAVELI®…

WALTHAM, Mass. and STOCKHOLM, Sweden, June 10, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today reported new analyses of Phase 3 studies that reinforce the robust efficacy and safety…

Accepted abstracts include an oral presentation highlighting quality of life improvements with EMPAVELI® (pegcetacoplan) WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global…

WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new…

WALTHAM, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present virtually at the 40th Annual J.P.…

Pegcetacoplan, an investigational, targeted C3 therapy, has the potential to become the first treatment for GA, a leading cause of blindness worldwide WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc.…

WALTHAM, Mass. and STOCKHOLM, Sweden, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that the Committee for Medicinal Products for…

Results further support the efficacy and safety profile of pegcetacoplan, an investigational, targeted C3 therapy, with monthly and every-other-month treatment Pegcetacoplan has the potential to become the first treatment for GA, a…

OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively, compared to pooled sham at 12…

EMPAVELI, the first targeted C3 therapy, is approved for use in adults with PNH who are:Treatment naïveSwitching from C5 inhibitor Soliris® (eculizumab) Switching from C5 inhibitor Ultomiris® (ravulizumab) EMPAVELI was superior to…